Steris PLC (NYSE:STE) stock fell 9.06% (As on February 9, 11:31:32 AM UTC-4, Source: Google Finance) after the company’s bottom line totaled $123.83 million, compared with $143.62 million, in last year’s third quarter. The company significantly improved capital equipment shipments for several key Healthcare products reflecting improved supply chain conditions. Some constraints remain for electronic components and other supply chain issues which, when combined with a reduction in the rate of growth for bioprocessing volumes, are impacting the performance for the third quarter and fiscal year. Challenges aside, the company is encouraged by a modest improvement in procedures and significant capital equipment backlog in both Healthcare and Life Sciences. The company anticipates continued supply chain improvements, which will aid in reducing the backlog and allow the company to achieve more normal lead times for the Customers over the coming quarters.

STE in the third quarter of FY 23 has reported the adjusted earnings per share of $2.02, missing the analysts’ estimates for the adjusted earnings per share of $2.19, according to figures compiled by Thomson Reuters. The company had reported the adjusted revenue growth of 1 percent to $1.22 billion in the third quarter of FY 23. Constant currency organic revenue increased 7% for the third quarter of fiscal 2023 as compared to the third quarter of fiscal 2022.

Moreover, Healthcare revenue as reported grew 1% in the quarter to $769.1 million compared with $759.7 million in the third quarter of fiscal 2022. This performance reflected a 5% improvement in capital equipment revenue and a 5% increase in service revenue, which were offset by a 5% decline in consumable revenue driven primarily by the Renal Divestiture and foreign currency. Healthcare operating income was $175.4 million compared with $175.8 million in last year’s third quarter. This decline was primarily attributable to the impact of increased supply chain and inflationary costs, which more than offset an increase in volume and price. Fiscal 2023 third quarter revenue for Applied Sterilization Technologies (AST) increased 3% as reported to $222.0 million compared with $216.3 million in the same period last year. This performance was driven primarily by increased demand from medical device Customers for the services somewhat offset by declines in Mevex capital equipment shipments due to timing and a reduction in the rate of growth of bioprocessing Customers. Life Sciences third quarter revenue as reported declined 5% to $121.3 million compared with $127.9 million in the third quarter of fiscal 2022. This performance reflected a 2% increase in service revenue, which was offset by a 6% decrease in capital equipment revenue and a 9% decline in consumable revenue.